Physician profile
Leonel K Vance
NPI 1669507943
$21,070.66
in general payments reported to CMS, 2019-2025
26 companies · $2,160 in 2025
The $2,160 reported for 2025 was more than what 80% of Interventional Pain Medicine providers received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15K · 2020: $724 · 2021: $1,178 · 2022: $862 · 2023: $634 · 2024: $236 · 2025: $2,160.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,851 · Travel and Lodging: $1,179.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,850.60 |
| Travel and Lodging | $1,178.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $13,930.96 | 2019 | |
| Abbott Laboratories | $2,989.39 | 2019-2024 | Proclaim, Eterna |
| Spinal Simplicity, LLC | $1,071.69 | 2025 | Ha Minuteman G3-R |
| Medtronic, INC. | $682.79 | 2022-2024 | Intellis Adaptivestim |
| Stryker Corporation | $479.90 | 2025 | Mild Device Kit |
| Collegium Pharmaceutical, INC. | $358.32 | 2019-2025 | Xtampza |
| Biotronik Nro, INC. | $332.65 | 2025 | Prospera |
| Si-Bone, INC. | $251.55 | 2025 | |
| Avanir Pharmaceuticals, INC. | $124.99 | 2019 | |
| Grt US Holding, INC. | $109.95 | 2022 | |
| Arbor Pharmaceuticals, INC. | $99.66 | 2019-2021 | |
| Daiichi Sankyo INC. | $86.03 | 2019 | |
| Biodelivery Sciences International, INC. | $81.98 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $79.65 | 2019-2021 | |
| Hikma Pharmaceuticals USA | $72.52 | 2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $55.98 | 2019 | |
| Shionogi INC | $45.64 | 2019 | |
| Pfizer INC. | $43.96 | 2019-2020 | |
| Biohaven Pharmaceuticals, INC. | $36.54 | 2021 | |
| Assertio Therapeutics, INC. | $28.26 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $26.11 | 2019 | |
| Amgen INC. | $22.07 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $17.39 | 2023 | Seglentis |
| Nalu Medical, INC. | $17.37 | 2024 | Nalu Neurostimulation System |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.36 | 2022 | |
| Lilly USA, LLC | $11.95 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leonel Vance listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.